Skip to main content

NanoViricides, Inc.

corporate_fare Company Profile

NanoViricides, Inc.

NNVC·NYSE·Life Sciences·CIK 0001379006

NanoViricides, Inc. is a clinical stage company incorporated in Nevada on April 1, 2005, and redomiciled to Delaware effective May 30, 2023. Its corporate offices are located at 1 Controls Drive, Shelton, Connecticut 06484. The company's common stock began trading on the New York Stock Exchange American under the symbol "NNVC" on September 25, 2013. NanoViricides is engaged in developing a class of drugs it calls nanoviricides™, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. This approach enables rapid development of effective new drugs against a number of different viruses that the viruses are highly unlikely to escape even as they evolve rapidly in the field, solving an important problem in attacking viruses. In contrast, viruses readily escape vaccines, antibodies and small chemical drugs developed using traditional antiviral approaches because, generally speaking, a small number of mutations allow the virus to become resistant, and thereupon resistant viruses can continue to grow and expand. The company is developing (a) host-mimetic, and (b) direct-acting, nanomachines capable of dismantling a targeted virus, (c) without assistance from the human immune system. Its first drug, NV-387, has previously successfully completed a Phase Ia/Ib clinical trial for human clinical safety and tolerability, wherein the drug was found to be safe and well tolerated, with no reportable adverse events, and no subjects dropping out. Phase II clinical trials of NV-387 are underway. Additionally, drug candidates are in various stages of pre-clinical development, including IND-filing stage and late stage IND-enabling non-clinical studies. The company has no customers, products or revenues to date, and may never achieve revenues or profitable operations.

NanoViricides, Inc. (NYSE:NNVC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for NNVC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for NNVC spans 424B5, 10-Q.

Recent high-impact activity:

  • NanoViricides Refreshes ATM Capacity to $8.4M Under S-3 Float Cap
  • NanoViricides Q1 Loss Widens to $5.7M; Going-Concern Doubt and ATM Sales Begin

Financial Snapshot

Fiscal year ended June 30, 2026
Net Income
-$8.22M
Diluted EPS
-$0.41
Op. Cash Flow
-$7.7M
Free Cash Flow
-$7.78M
Operating Income
-$8.31M
Cash & Equivalents
$2.79M
Debt / Equity
0.00×
Shares Outstanding
23.01M sh
Source: 10-K · filed 2026-09-28 · accession 0001104659-26-111390

Short Interest & Short Volume

4.19 days to cover

FINRA reported short interest of 812,252 shares in NNVC as of the October 30, 2026 settlement, a 28.9% decrease from the prior period — about 4.2 days to cover at its recent average daily volume. On November 20, 2026, 31.8% of NNVC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)812,252 shares as of October 30, 2026
Change vs prior period▼ 28.9%
Days to cover4.19 at avg daily volume of 193,927
Daily short volume (FINRA facilities)31.8% of 63,874 shares on November 20, 2026
5-day average short volume51.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for NNVC, detected from its recent SEC filings · based on capital-structure filings through 2026-11-17.

1 recent capital raise

ATM Capacity Reset to $8.4M · Float Cap Drives the Limit

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

$1.13 -0.88% today
52-week range · as of 2026-11-17 $0.85 – $1.93
Market cap
$29.13M
Volume
106.8K (0.6× avg)
3-mo avg 168.9K
Live data · 2026-11-22 12:34 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NNVC - Latest Insights

NNVC
Nov 17, 2026, 4:34 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $1.13 info
Change: -$0.030 (-3%) info
Market Cap: $29.133M info
NNVC
Nov 16, 2026, 5:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $1.13 info
Change: -$0.100 (-8%) info
Market Cap: $29.133M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets